Show results for
Refine by
Locations
- Africa
- Algeria
- Angola
- Benin
- Botswana
- Burkina Faso
- Burundi
- Cameroon
- Cape Verde
- Central African Republic
- Chad
- Comoros
- Congo
- Congo, Democratic Republic Of The
- Djibouti
- Egypt
- Equatorial Guinea
- Eritrea
- Ethiopia
- Gabon
- Gambia
- Ghana
- Guinea
- Guinea-Bissau
- Ivory Coast
- Kenya
- Lesotho
- Liberia
- Libya
- Madagascar
- Malawi
- Mali
- Mauritania
- Mauritius
- Morocco
- Mozambique
- Namibia
- Niger
- Nigeria
- Rwanda
- Senegal
- Seychelles
- Sierra Leone
- Somalia
- South Africa
- St. Helena
- Sudan
- Swaziland
- SãO Tomé & PríNcipe
- Tanzania
- Togo
- Tunisia
- Uganda
- Zaire
- Zambia
- Zimbabwe
Therapeutic Potential Equipment & Supplies In Africa
103 equipment items found
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
DEP® docetaxel is an enhanced version of docetaxel (Taxotere®) – widely used for breast, lung & prostate cancer. Docetaxel (Taxotere®) is a commonly used chemotherapy agent despite having multiple US FDA “Black Box” warnings. DEP® docetaxel is a detergent free, aqueous formulation of docetaxel. ...
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS-704 is a ghrelin O-acyl transferase inhibitor with therapeutic potential for multiple ...
Manufactured by:Altucell, Inc. based inNew York, NEW YORK (USA)
Encapsulated cell therapy is an emerging area of biopharmaceutical research that aims to unleash the therapeutic potential of cells to treat serious diseases without the need for immunosuppression. Altucell has developed patented, proprietary engineered cells that are combined with a patented encapsulation technology to create effective ...
by:Orion Biotechnology Canada, Ltd. based inOttawa, SWITZERLAND
Orion’s platform and science unlocks the therapeutic potential of GPCR targets across a broad range of medical needs. Our approach allows us to focus our discovery and development efforts across peptide and protein GPCR subfamilies, generating a diversified pipeline of potential first-in-class/best-in-class antagonist and ...
by:Vir Biotechnology, Inc. based inSan Francisco, CALIFORNIA (USA)
We have established a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. We identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso5 is a discovery-stage program leveraging a specific keystone gut bacteria (undisclosed) to potentiate the effects of Immune Checkpoint Blockade (ICB) drugs. The field of cancer therapy has been revolutionized by the use of immunotherapy. The microbiome breakthrough science today paves the way for innovative biotherapies to potentiate the effectiveness of ...
Manufactured by:Sangamo Therapeutics based inBrisbane, CALIFORNIA (USA)
Sangamo’s proprietary zinc finger (ZF) platform uniquely confers a number of advantages and has broad therapeutic potential due to its versatility, specificity and clinical utility. Zinc finger technologies are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
Glycosylation is increasingly recognised as a modulator of the malignant phenotype of cancer cells, where the interaction between cells and the tumour micro-environment is altered to facilitate processes such as drug resistance, metastasis and immune evasion. Antibodies recognising tumour-associated glycans could therefore have excellent therapeutic ...
Manufactured by:Toleris Biotherapeutics GmbH based inWürzburg, GERMANY
They are engineered to exploit natural immune tolerance mechanisms to stop autoimmune disease progression while minimizing side effects and maximizing therapeutic potential. Studies in model systems have shown promising results in inducing antigen-specific tolerance and reducing autoimmune ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
This approach overcomes the limitations of traditional platforms by rapidly creating fully human antibodies that tightly bind to therapeutic targets and avoid potential immune responses that may occur in patients receiving antibodies that contain nonhuman (typically mouse) ...
Manufactured by:PeptaNova GmbH based inSandhausen, GERMANY
This compound, characterized by its (2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl-L-valyl-L-phenylalanine structure, is soluble in water, methanol, and DMSO, offering versatile application potentials in different environments. Phebestin can be used in various biochemical assays where selective inhibition of APN is desired, making it integral for research in cellular signaling and ...
Manufactured by:SpliceBio based inBarcelona, SPAIN
The company has focused on the innovative application of inteins, a class of proteins that can perform protein splicing through biochemical reactions involving cleavage and bond formation. Historically, natural inteins presented several limitations, making them unsuitable for human therapeutics. SpliceBio's co-founders have overcome these barriers by developing advanced ...
by:Neoclease based inBoston, MASSACHUSETTS (USA)
The focus on innovation extends to the creation of comprehensive nuclease libraries, ensuring a wide range of tools for various applications. The company aims to shift the paradigm in therapeutic development, moving towards potential curative solutions for genetic diseases. As Neoclease continues to advance its technology, it invites investors and collaborators ...
Manufactured by:Bayer AG based inLeverkusen, GERMANY
Small molecules (SMOLs) have long been in the focus of modern medicine. Over the last century, their advent revolutionized healthcare and improved the lives of patients all over the world. Most of today´s SMOLs exert their function by binding to proteins, thereby modulating their ability to catalyze biochemical reactions. However, a lot of proteins are difficult targets for SMOLs, since ...
Manufactured by:Celularity Inc. based inFlorham Park, NEW JERSEY (USA)
Celularity’s unique technology realizes the full promise of cell therapies by harnessing the immunomodulatory and regenerative properties of the postpartum ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
VelociMab is a group of technologies that allow us to move with unprecedented speed from identification of a therapeutic antibody into clinical studies. VelociMab enables the high-throughput screening of potential therapeutic antibodies and the rapid generation of cell lines for recombinant human antibodies. It allows researchers to go from mouse ...
Manufactured by:AIDFLEX LTD based inObninsk, RUSSIA
The Aidflex G9 Dynamic Arm Support Trainer is designed to compensate for arm weight. Suitable for all people with motor disorders in the upper limbs, leading to a non-physiological limitation of the range of motion and the ability to position the hand in a given position. To use the simulator, minimal movements in the muscles of the shoulder girdle, in the proximal part of the shoulder and simple ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Three transgenes: Producing IL-12, IL-15 and a chemokine. As part of our expanding T-SIGn platform pipeline, this candidate is progressing through its IND enabling activities in readiness for entering clinical ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Novel transgene combinations. Our research team are developing a suite of viral vectors with new and innovative transgene ...